Acute myeloid leukemia (AML) is the most common form of adult leukemia, and with an estimated five-year survival rate of 20%, the long-term prognosis for many patients is relatively grim.
“Current treatments for AML can initially reduce the number of AML cells to undetectable levels, a state referred to as ‘complete remission’,” says Fumihiko Ishikawa of the RIKEN Research Center for Allergy and Immunology in Yokohama. “Unfortunately, in a substantial proportion of these patients, AML eventually comes back—and many that relapse succumb to the disease.” The need for an improved arsenal to fight AML has guided much of Ishikawa’s work, and two recently published articles from his team present promising strategies for tackling this dreaded cancer.
AML originates in bone marrow, and relapse is initiated from small pockets of chemotherapy-resistant ‘leukemia stem cells’ (LSCs) within the marrow, which can be identified by their distinctive profile of cell-surface markers. In an effort to identify other features of LSCs that might offer useful therapeutic targets, Ishikawa, Yoriko Saito and team performed a thorough comparative analysis between LSCs and normal blood stem cells to identify genes with functional characteristics pertinent to cancerous growth whose expression is specifically elevated in LSCs1.
Their analysis revealed two candidate cell-surface proteins, CD25 and CD32; both of these are commonly overexpressed in chemotherapy-resistant LSCs, but can also be therapeutically targeted without negatively affecting blood cell development from healthy hematopoietic stem cells, making them potentially promising targets for thwarting relapse.
In parallel, Ishikawa and colleagues have also explored methods for boosting the efficiency of chemotherapy. Standard AML drugs such as cytosine arabinoside (Ara-C) work by targeting actively dividing cells, and LSCs are believed to elude chemotherapy by entering a quiescent, non-dividing state. The researchers hypothesized that LSCs could be made more vulnerable to Ara-C via simultaneous treatment with cytokines—naturally-occurring cell signaling molecules—that stimulate them into active division2. In fact, this two-pronged treatment led to a ten-fold increase in survival rate relative to chemotherapy alone for mice that had been transplanted with human LSCs.
Previous studies have suggested that despite some risk of toxicity, cytokine treatment is relatively safe for patients, and Ishikawa’s team is actively investigating the practicality and safety of interventions based on both of their recent discoveries. “We have been putting our best effort into the translation of these findings into medicine,” he says. “At the same time, we are continuing to try to identify unknown aspects of human AML and AML stem cells.”
The corresponding author for this highlight is based at the Research Unit for Human Disease Model, RIKEN Research Center for Allergy and Immunology
1. Saito, Y., Kitamura, H., Hijikata, A., Tomizawa-Murasawa, M., Tanaka, S., Takagi, S., Uchida, N., Suzuki, N., Sone, A., Najima, Y. et al. Identification of therapeutic targets for quiescent chemotherapy-resistant human leukemia stem cells. Science Translational Medicine 2, 17ra9 (2010).
2. Saito, Y., Uchida, N., Tanaka, S., Suzuki, N., Tomizawa-Murasawa, M., Sone, A., Najima, Y., Takagi, S., Aoki, Y., Wake, A. et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nature Biotechnology 28, 275–280 (2010).
gro-pr | Research asia research news
Scientists learn more about how gene linked to autism affects brain
19.06.2018 | Cincinnati Children's Hospital Medical Center
Overdosing on Calcium
19.06.2018 | Albert-Ludwigs-Universität Freiburg im Breisgau
Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...
Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.
Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...
The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.
Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.
An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.
Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...
Light detection and control lies at the heart of many modern device applications, such as smartphone cameras. Using graphene as a light-sensitive material for...
13.06.2018 | Event News
08.06.2018 | Event News
05.06.2018 | Event News
19.06.2018 | Physics and Astronomy
19.06.2018 | Life Sciences
19.06.2018 | Physics and Astronomy